L-DOPA/Capsazepine or L-DOPA/Rimonabant Co-Administration in an Experimental Parkinson Disease Model: Behavioral and Cellular Consequences

The ability of rimonabant or capsazepine with the addition of L-DOPA in: (1) the severity of LIDs, the dyskinetic effects were assessed using measures of abnormal involuntary movements (AIMs); (2) the protection of dopaminergic cell loss; and (3) the cytological

Read More